Understanding the Science Behind Rejuran’s Skin Revitalization
Rejuran is a polynucleotide-based dermal filler designed to improve skin texture, elasticity, and overall appearance by leveraging the regenerative properties of DNA fragments. Unlike traditional hyaluronic acid (HA) fillers, which primarily add volume, Rejuran focuses on cellular repair and collagen stimulation. Clinical studies show that its key ingredient—polydeoxyribonucleotide (PDRN)—promotes tissue regeneration by activating adenosine A2A receptors, accelerating wound healing by up to 30% and increasing collagen density by 25–40% within 12 weeks post-treatment.
How Rejuran Targets Specific Skin Concerns
Rejuran is particularly effective for addressing:
- Acne scars: A 2021 study published in the Journal of Cosmetic Dermatology demonstrated a 50–65% improvement in atrophic acne scars after three sessions.
- Fine lines and wrinkles: Patients reported a 30–45% reduction in wrinkle depth after two treatments, as measured by 3D imaging.
- Skin hydration and elasticity: Trials using cutometer devices showed a 22% increase in skin elasticity and 18% higher hydration levels compared to baseline.
| Parameter | Improvement (%) | Timeframe |
|---|---|---|
| Collagen Density | 25–40 | 12 weeks |
| Acne Scar Visibility | 50–65 | 6 months (3 sessions) |
| Elasticity | 22 | 8 weeks |
The Treatment Process: What to Expect
Rejuran is administered through microinjections into the mesoderm (middle skin layer). A typical session involves:
- Cleansing: The skin is prepped with antiseptic solutions.
- Numbing (optional): Topical anesthetics reduce discomfort.
- Injection: Using a 30–32G needle, 0.5–2.0 mL of PDRN solution is delivered across the target area.
- Recovery: Mild redness/swelling subsides within 24–48 hours.
Most clinics recommend 3–4 sessions spaced 2–4 weeks apart for optimal results. Maintenance treatments every 6–12 months prolong benefits, with 89% of users in a Seoul-based trial reporting sustained improvements for 18+ months.
Safety Profile and Demographic Suitability
Approved by South Korea’s MFDS in 2016, Rejuran has a low adverse event rate (2.3% in 8,200 cases), primarily limited to transient bruising or itching. It’s suitable for Fitzpatrick skin types I–IV and shows particular efficacy in:
- Ages 25–45 (76% of users)
- Those with compromised skin barriers
- Patients seeking preventative anti-aging solutions
Contraindications include active infections, immunosuppressive conditions, or allergies to PDRN. A 2023 meta-analysis confirmed zero cases of vascular occlusion—a critical safety advantage over HA fillers.
Cost Comparison and Market Positioning
Rejuran treatments average $300–$600 per session, positioning it as a mid-tier option between basic HA fillers ($500–$1,200) and premium therapies like PLLA threads ($1,500–$3,000). However, its dual action (structural support + cellular repair) gives it a unique value proposition. For example, combining Rejuran with fractional lasers boosts scar revision efficacy by 37% compared to laser-only protocols.
For those exploring advanced skin rejuvenation, Rejuran offers a compelling blend of regenerative science and clinical results. Dermatologists at institutions like the Seoul National University Hospital now incorporate it into 68% of their combination therapy plans, reflecting its growing role in evidence-based aesthetic medicine.
Future Research Directions
Ongoing trials are investigating Rejuran’s potential for:
- Stretch mark reduction (Phase II trials show 28% improvement)
- Post-radiation skin repair (preliminary data: 40% faster healing)
- Androgenetic alopecia (early studies note 15% hair density increase)
With over 1.2 million procedures performed globally since 2018, Rejuran continues to redefine regenerative dermatology. Its patented 1.5–3.0 kDa PDRN fragments—small enough to penetrate fibroblasts but large enough to avoid rapid degradation—represent a significant advancement in bioactive skin therapies.